Clinical Study Results
Study Name
Title of the Study: A Randomized, Double-blind Study Evaluating the Efficacy, Safety,
and Immunogenicity of ABP 798 Compared with
Rituximab in Subjects with CD20 Positive B-cell Non-Hodgkin
Lymphoma (NHL)
Brief Title: Study to Assess if ABP 798 is Safe & Effective in Treating Non-
Hodgkin Lymphoma Compared to Rituximab (JASMINE)
Protocol Number: 20130109
EU Trial Number 2013-005542-11
Other Identifiers NCT02747043
Date of This Summary 27 April 2020
What does this summary cover?
devorppA
This summary shows the main results from one clinical study. The results are only for
this study. Other studies may find different results. Researchers and health authorities
look at the results of many studies to decide which medicines work best and are safest
for patients.
1. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study and manufactured ABP 798, the investigational
medicine included in the study. Amgen would like to thank everyone who participated in
this study and feels it is important to share the results of this study.
1